Effects of the Bifidobacterium Longum BL21 on BMI, Metabolic Indicators, and Gut Microbiota in Overweight/Obese Adults

The goal of this study is to investigate the effects of Bifidobacterium longum subspecies BL21 on BMI, metabolic indicators, and changes in gut microenvironment microbiota in overweight/obese adults. The blood, urine, and feces samples of the subjects need to be collected at 0,4 and 8 week and promptly tested in the laboratory. During the intervention period, all groups of subjects were required to take the corresponding products daily and record adverse reactions.

Inclusion Criteria: 1. Body mass index (BMI) ≥ 24kg/m2 indicates overweight, and BMI ≥ 28kg/m2 indicates obesity; 2. Willing to take the test formulation daily during the study period; 3. Subjects who understand clinical research and commit to complying with research requirements and procedures. Exclusion Criteria: 1. Patients with serious chronic diseases (heart, liver, kidney, hematopoietic system, tumor and other serious diseases, mental disease and organ surgery history, diabetes, etc.) and complications; 2. Patients with severe allergies and immune deficiencies; 3. Pregnant, breastfeeding, or expectant women during the study period 4. Patients with a clear history of gastrointestinal diseases (ulcers, irritable bowel syndrome, etc.); 5. Have a history of intervention with lipid-lowering drugs or health products within the past 2 months; 6. Individuals who have used antibiotics within the past two weeks; 7. Failure to consume the test sample as required, or failure to follow up on time, resulting in uncertain efficacy 8. Subjects deemed unsuitable by other researchers to participate.